Crucell signs antibody license with Genzyme

By Ted A. Knutson

Washington, Dec. 19 - Crucell NV announced Monday that it has signed a non-exclusive STAR research license agreement for the production of monoclonal antibodies with Cambridge, Mass.-based Genzyme Corp.

Financial details were not disclosed.

Crucell is a biotechnology company based in Leiden, The Netherlands, that develops vaccines and antibodies.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.